Latest Articles

Publication Date
Women with endometriosis face fourfold higher risk of ovarian cancer, study suggests - CNN

Women with endometriosis face fourfold higher risk of ovarian cancer, study suggests CNN

Published: July 17, 2024, 7 a.m.
Women With Endometriosis Face ‘Markedly Increased’ Risk Of Ovarian Cancer, Study Suggests - Forbes

Women With Endometriosis Face ‘Markedly Increased’ Risk Of Ovarian Cancer, Study Suggests Forbes

Published: July 17, 2024, 7 a.m.
6 Things That Can Cause Ovarian Cysts - Health.com

6 Things That Can Cause Ovarian Cysts Health.com

Published: July 14, 2024, 7 a.m.
ROCSAN Study Step I Misses 16-Week ORR End Point in Endometrial or Ovarian Carcinosarcoma - OncLive

ROCSAN Study Step I Misses 16-Week ORR End Point in Endometrial or Ovarian Carcinosarcoma OncLive

Published: June 20, 2024, 7 a.m.
Endometriosis increases risks for ovarian, endometrial cancers - Healio

Endometriosis increases risks for ovarian, endometrial cancers Healio

Published: June 7, 2024, 7 a.m.
FDA grants breakthrough designation for ovarian cancer liquid biopsy - TechTarget

FDA grants breakthrough designation for ovarian cancer liquid biopsy TechTarget

Published: May 31, 2024, 7 a.m.
For some endometriosis-related ovarian cancers, timing is everything - Medical Xpress

For some endometriosis-related ovarian cancers, timing is everything Medical Xpress

Published: May 28, 2024, 7 a.m.
Estrogen-Only Therapy for Menopausal Symptoms Increases Ovarian Cancer Risk - Medpage Today

Estrogen-Only Therapy for Menopausal Symptoms Increases Ovarian Cancer Risk Medpage Today

Published: May 24, 2024, 7 a.m.
Mayo scientists explore swabs for early endometrial, ovarian cancer detection - Mayo Clinic

Mayo scientists explore swabs for early endometrial, ovarian cancer detection Mayo Clinic

Published: May 23, 2024, 7 a.m.
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer - GlobeNewswire

eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous …

Published: May 20, 2024, 7 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!